NYSE · MRKHealthcarePharmaceuticals

Merck & Co. financials

$149.28+0.40%
Close Sep 29, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

QuarterQ2 '26
Jun 30
Q1 '26
Mar 31
Q4 '25
Dec 31
Q3 '25
Sep 30
Q2 '25
Jun 30
Q1 '25
Mar 31
Q4 '24
Dec 31
Q3 '24
Sep 30
Q2 '24
Jun 30
Q1 '24
Mar 31
Q4 '23
Dec 31
Q3 '23
Sep 30
Revenue$16.61B$16.29B$16.40B$17.28B$15.81B$15.53B$15.62B$16.66B$16.11B$15.78B$14.63B$15.96B
Gross profit$12.21B$12.09B$10.85B$13.42B$12.25B$12.11B$11.80B$12.58B$12.37B$12.23B$10.72B$11.70B
Gross margin73.5%74.2%66.2%77.7%77.5%78.0%75.5%75.5%76.8%77.6%73.3%73.3%
Operating income-$584.0M-$3.40B$3.85B$6.51B$4.99B$5.87B$4.30B$3.93B$6.05B$5.64B-$1.97B$5.75B
Net income-$1.33B-$4.24B$2.96B$5.79B$4.43B$5.08B$3.74B$3.16B$5.46B$4.76B-$1.23B$4.75B
Net margin−8.0%−26.0%18.1%33.5%28.0%32.7%24.0%19.0%33.9%30.2%−8.4%29.7%
Diluted EPS$-0.54$-1.72$1.19$2.32$1.76$2.01$1.48$1.24$2.14$1.87$-0.48$1.86
EBITDA$1.15B-$1.69B$6.53B$7.71B$6.67B$7.04B$5.54B$5.17B$7.26B$6.74B-$749.0M$6.89B
Operating cash flow$5.37B$3.92B$2.86B$7.82B$3.29B$2.50B$3.45B$9.29B$5.64B$3.09B$246.0M$7.72B
Free cash flow$4.48B$2.93B$1.82B$6.83B$2.53B$1.17B$2.51B$8.51B$4.85B$2.23B-$743.0M$6.82B
Diluted shares2,470.0M2,472.0M2,486.0M2,498.0M2,513.0M2,531.0M2,535.0M2,541.0M2,544.0M2,544.0M2,552.0M2,546.0M

Balance sheet

Period endJun 30Mar 31Dec 31Sep 30Jun 30Mar 31
Cash & equivalents$6.85B$5.33B$14.56B$18.17B$8.01B$8.63B
Short-term investments$292.0M$375.0M$0.00$45.0M$615.0M$599.0M
Total debt$53.91B$49.12B$49.34B$41.37B$35.40B$34.84B
Total assets$129.80B$128.69B$136.87B$129.55B$117.52B$115.12B
Total liabilities$87.82B$82.75B$84.20B$77.64B$68.46B$66.72B
Shareholders' equity$41.98B$45.93B$52.66B$51.91B$49.06B$48.40B

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology